Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms
In advanced pancreatic neuroendocrine neoplasms (PanNEN), there are little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA colle...
Uloženo v:
| Vydáno v: | Endocrine-related cancer Ročník 31; číslo 4 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
01.04.2024
|
| Témata: | |
| ISSN: | 1479-6821, 1479-6821 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | In advanced pancreatic neuroendocrine neoplasms (PanNEN), there are little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA samples were analyzed from 25 patients, the majority who had well-differentiated intermediate grade disease (13/25; 52%). Genomic alterations were detected in 68% of patients and in 66% of all cfDNA samples. The most frequently altered genes were DAXX (28%), TSC2 (24%), MEN1 (24%), ARID1B (20%), ARID1A (12%), and ATRX (12%). Twenty-three out of 25 (92%) patients underwent tumor tissue NGS. Tissue-plasma concordance for select genes was as follows:DAXX (95.7%), ARID1A (91.1%), ATRX (87%), TSC2 (82.6%), MEN1 (69.6%). Potentially actionable alterations were identified in cfDNA of 8 patients, including TSC2 (4; level 3b), ATM (1; level 3b), ARID1A (2; level 4), and KRAS (1; level 4). An ETV6:NTRK fusion detected in tumor tissue was treated with larotrectinib; at progression, sequencing of cfDNA identified an NTRK3 G623R alteration as the acquired mechanism of resistance; the patient enrolled in a clinical trial of a second-generation TRK inhibitor with clinical benefit. In metastatic PanNENs, cfDNA-based NGS identified tumor-associated mutations in 66% of plasma samples with a high level of plasma-tissue agreement in PanNEN-associated genes. Clonal evolution, actionable alterations, and resistance mechanisms were detected through circulating cfDNA genotyping. |
|---|---|
| AbstractList | In advanced pancreatic neuroendocrine neoplasms (PanNEN), there are little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA samples were analyzed from 25 patients, the majority who had well-differentiated intermediate grade disease (13/25; 52%). Genomic alterations were detected in 68% of patients and in 66% of all cfDNA samples. The most frequently altered genes were DAXX (28%), TSC2 (24%), MEN1 (24%), ARID1B (20%), ARID1A (12%), and ATRX (12%). Twenty-three out of 25 (92%) patients underwent tumor tissue NGS. Tissue-plasma concordance for select genes was as follows:DAXX (95.7%), ARID1A (91.1%), ATRX (87%), TSC2 (82.6%), MEN1 (69.6%). Potentially actionable alterations were identified in cfDNA of 8 patients, including TSC2 (4; level 3b), ATM (1; level 3b), ARID1A (2; level 4), and KRAS (1; level 4). An ETV6:NTRK fusion detected in tumor tissue was treated with larotrectinib; at progression, sequencing of cfDNA identified an NTRK3 G623R alteration as the acquired mechanism of resistance; the patient enrolled in a clinical trial of a second-generation TRK inhibitor with clinical benefit. In metastatic PanNENs, cfDNA-based NGS identified tumor-associated mutations in 66% of plasma samples with a high level of plasma-tissue agreement in PanNEN-associated genes. Clonal evolution, actionable alterations, and resistance mechanisms were detected through circulating cfDNA genotyping.In advanced pancreatic neuroendocrine neoplasms (PanNEN), there are little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA samples were analyzed from 25 patients, the majority who had well-differentiated intermediate grade disease (13/25; 52%). Genomic alterations were detected in 68% of patients and in 66% of all cfDNA samples. The most frequently altered genes were DAXX (28%), TSC2 (24%), MEN1 (24%), ARID1B (20%), ARID1A (12%), and ATRX (12%). Twenty-three out of 25 (92%) patients underwent tumor tissue NGS. Tissue-plasma concordance for select genes was as follows:DAXX (95.7%), ARID1A (91.1%), ATRX (87%), TSC2 (82.6%), MEN1 (69.6%). Potentially actionable alterations were identified in cfDNA of 8 patients, including TSC2 (4; level 3b), ATM (1; level 3b), ARID1A (2; level 4), and KRAS (1; level 4). An ETV6:NTRK fusion detected in tumor tissue was treated with larotrectinib; at progression, sequencing of cfDNA identified an NTRK3 G623R alteration as the acquired mechanism of resistance; the patient enrolled in a clinical trial of a second-generation TRK inhibitor with clinical benefit. In metastatic PanNENs, cfDNA-based NGS identified tumor-associated mutations in 66% of plasma samples with a high level of plasma-tissue agreement in PanNEN-associated genes. Clonal evolution, actionable alterations, and resistance mechanisms were detected through circulating cfDNA genotyping. In advanced pancreatic neuroendocrine neoplasms (PanNEN), there are little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA samples were analyzed from 25 patients, the majority who had well-differentiated intermediate grade disease (13/25; 52%). Genomic alterations were detected in 68% of patients and in 66% of all cfDNA samples. The most frequently altered genes were DAXX (28%), TSC2 (24%), MEN1 (24%), ARID1B (20%), ARID1A (12%), and ATRX (12%). Twenty-three out of 25 (92%) patients underwent tumor tissue NGS. Tissue-plasma concordance for select genes was as follows:DAXX (95.7%), ARID1A (91.1%), ATRX (87%), TSC2 (82.6%), MEN1 (69.6%). Potentially actionable alterations were identified in cfDNA of 8 patients, including TSC2 (4; level 3b), ATM (1; level 3b), ARID1A (2; level 4), and KRAS (1; level 4). An ETV6:NTRK fusion detected in tumor tissue was treated with larotrectinib; at progression, sequencing of cfDNA identified an NTRK3 G623R alteration as the acquired mechanism of resistance; the patient enrolled in a clinical trial of a second-generation TRK inhibitor with clinical benefit. In metastatic PanNENs, cfDNA-based NGS identified tumor-associated mutations in 66% of plasma samples with a high level of plasma-tissue agreement in PanNEN-associated genes. Clonal evolution, actionable alterations, and resistance mechanisms were detected through circulating cfDNA genotyping. |
| Author | Capanu, Marinela Shah, Ronak H Cowzer, Darren DeMore, April Raj, Nitya Kundra, Ritika Reidy-Lagunes, Diane Punn, Sippy Chou, Joanne F Fiedler, Laura Berger, Michael F |
| Author_xml | – sequence: 1 givenname: Darren orcidid: 0000-0002-0969-3259 surname: Cowzer fullname: Cowzer, Darren organization: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA – sequence: 2 givenname: Ronak H surname: Shah fullname: Shah, Ronak H organization: Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA – sequence: 3 givenname: Joanne F surname: Chou fullname: Chou, Joanne F organization: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA – sequence: 4 givenname: Ritika surname: Kundra fullname: Kundra, Ritika organization: Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA – sequence: 5 givenname: Sippy surname: Punn fullname: Punn, Sippy organization: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA – sequence: 6 givenname: Laura surname: Fiedler fullname: Fiedler, Laura organization: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA – sequence: 7 givenname: April surname: DeMore fullname: DeMore, April organization: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA – sequence: 8 givenname: Marinela surname: Capanu fullname: Capanu, Marinela organization: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA – sequence: 9 givenname: Michael F surname: Berger fullname: Berger, Michael F organization: Department of Pathology and laboratory medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA – sequence: 10 givenname: Diane surname: Reidy-Lagunes fullname: Reidy-Lagunes, Diane organization: Weill Medical College of Cornell University, New York, New York, USA – sequence: 11 givenname: Nitya orcidid: 0000-0002-1385-9995 surname: Raj fullname: Raj, Nitya organization: Weill Medical College of Cornell University, New York, New York, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38252063$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUEtLxDAYDKK4Dz15lxy9RPNomua41PUBiwuy95KmXyGSpjVpD_vvrbqCp5mBmWGYFToPfQCEbhi9Z1LQh-17SbgglGt-hpYsU5rkBWfn__gCrVL6oJTmhZSXaCEKLjnNxRLtS--Cs8bjaXTejUfct3jwJnUGW_CetBEAP75tsAt4MMFGMKOzOMAUewhNb6MLMMv-J5Su0EVrfILrE67R4Wl7KF_Ibv_8Wm52xAqmRgKNYdBmWijNWSYypkEXXJmaSsVtLWohazULkUPGQNVF3hhTyIZmVgO3fI3ufmuH2H9OkMaqc-l7r5mXTKnimikpudJytt6erFPdQVMN0XUmHqu_D_gXCptesQ |
| CitedBy_id | crossref_primary_10_3390_ijms26167814 crossref_primary_10_1002_path_6348 crossref_primary_10_1210_clinem_dgae241 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1530/ERC-23-0292 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1479-6821 |
| ExternalDocumentID | 38252063 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA008748 |
| GroupedDBID | --- 0R~ 18M 2WC 4.4 5GY 5VS AALGN ABOCM ABSQV ACGFO ADBBV ADDZX ADMOG AENEX AFHIN ALMA_UNASSIGNED_HOLDINGS BAWUL CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF F5P F9R GX1 HZ~ INIJC KQ8 NPM O9- OK1 P2P REN TBS TR2 W8F WOQ 7X8 |
| ID | FETCH-LOGICAL-c317t-eda1ef493792143419e9827ab0572cb3b35b7b0536e41e7b86daa85d04c9e2c2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 4 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001207780500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1479-6821 |
| IngestDate | Thu Jul 10 19:56:55 EDT 2025 Mon Jul 21 06:00:05 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | cell-free DNA precision oncology circulating-tumor DNA pancreatic neuroendocrine neoplasms next generation sequencing |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c317t-eda1ef493792143419e9827ab0572cb3b35b7b0536e41e7b86daa85d04c9e2c2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-1385-9995 0000-0002-0969-3259 |
| PMID | 38252063 |
| PQID | 2917552795 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2917552795 pubmed_primary_38252063 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-04-01 |
| PublicationDateYYYYMMDD | 2024-04-01 |
| PublicationDate_xml | – month: 04 year: 2024 text: 2024-04-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Endocrine-related cancer |
| PublicationTitleAlternate | Endocr Relat Cancer |
| PublicationYear | 2024 |
| SSID | ssj0006855 |
| Score | 2.443682 |
| Snippet | In advanced pancreatic neuroendocrine neoplasms (PanNEN), there are little data detailing the frequency of genetic alterations identified in cell free DNA... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| SubjectTerms | Cell-Free Nucleic Acids - genetics Genome Genomics High-Throughput Nucleotide Sequencing Humans Mutation Neuroendocrine Tumors - genetics Pancreatic Neoplasms - genetics |
| Title | Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38252063 https://www.proquest.com/docview/2917552795 |
| Volume | 31 |
| WOSCitedRecordID | wos001207780500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ3dS8MwEMCDOhFf_P6YX0TwNaxN-pE8yZgbPrg6ZMjeSpMmIGg71-nf7yXN2JMg-FIINHAN18vv7pI7hO4U7GkRqAoJEhmTSJiSyJIKADkppTZMaRfveH1Ks4zPZmLiA26NP1a5sonOUJe1sjHyHgW_wlYLE_H9_JPYrlE2u-pbaGyiDgOUsVqdztbVwhPuup6GUSpIwmno7-fFLOgNXwaE2gymy4H-wpZujxnt_1e6A7Tn6RL3W3U4RBu6OkI7Y58_P0bPvgzoOwZ9swCOa4PnANAfBbYhfGIWWuOHrI_fKgx2okVKhV3VS12BHPayIAxrN6k5QdPRcDp4JL6lAlEACkuiyyLUJgImERRIKQqFFpymhQRso0oyyWKZwoAlOgp1KnlSFgWPyyBSQlNFT9FWVVf6HGGhwBVSPFEGXgUjyQ0rFY2pCXRKCyG76Ha1UjlorP2GAqT7avL1WnXRWbvc-bwtrZEzcFgpUNPFH2Zfol0KhNEeo7lCHQP_q75G2-p7-dYsbpwqwDObjH8A5qm-vA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+utility+of+plasma+cell-free+DNA+in+pancreatic+neuroendocrine+neoplasms&rft.jtitle=Endocrine-related+cancer&rft.au=Cowzer%2C+Darren&rft.au=Shah%2C+Ronak+H&rft.au=Chou%2C+Joanne+F&rft.au=Kundra%2C+Ritika&rft.date=2024-04-01&rft.issn=1479-6821&rft.eissn=1479-6821&rft.volume=31&rft.issue=4&rft_id=info:doi/10.1530%2FERC-23-0292&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-6821&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-6821&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-6821&client=summon |